2023 World Conference on Lung Cancer (Posters)-EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years

EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to evaluate the safety, efficacy, and pharmacokinetics (PK) of pembrolizumab (Pemb) in older adults aged over 75 years with non-small cell lung cancer (NSCLC). The study enrolled 100 patients and collected blood samples for PK analysis. The median age of the patients was 78 years, and the majority were male. The patients had adenocarcinoma or squamous cell carcinoma, and some had metastatic disease. The best overall efficacy of pembrolizumab was found to be a response rate of 47.5%, with a median progression-free survival of 8.0 months and overall survival of 19.0 months. The adverse event profile was similar to previous studies. <br /><br />The study found no clear association between pembrolizumab concentrations and patient background. However, patients with low pembrolizumab concentrations had significantly shortened progression-free survival and overall survival. This population had lower performance statuses, a high number of metastatic organs at the beginning of treatment, and low blood albumin levels. <br /><br />In conclusion, older adults aged over 75 years with NSCLC and low albumin levels, poor performance statuses, and a high number of metastatic organs may not benefit from pembrolizumab treatment. The study highlights the importance of considering patient characteristics, such as blood albumin levels, when determining the efficacy of immunotherapy in older adults with NSCLC.

Asset Subtitle

Hidehito Horinouchi

Meta Tag

Speaker Hidehito Horinouchi

Topic Metastatic NSCLC: Immunotherapy - Retrospective

Keywords

safety

efficacy

pharmacokinetics

pembrolizumab

older adults

NSCLC

response rate

progression-free survival

overall survival

metastatic organs